市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Biohaven Ltd. | 混合的 | 看跌 |
AIStockmoo 评分
| 价值 35% | -0.2 |
| AI Insight 参考 | NA |
| 相对估值 参考 | NA |
| 财务健康 参考 | -0.2 |
| 时机 35% | 2.8 |
| AI Technical 参考 | NA |
| 技术振荡指标 参考 | 4.0 |
| 技术平均移动指标 参考 | 1.0 |
| 聪明钱 30% | 0.0 |
| 分析师共识 参考 | 0.0 |
| 内部交易活动 参考 | NA |
| 市场环境 | ×0.79 |
| 宏观环境 参考 | -3.3 |
| 行业对比大市 (6个月) | -22.4% |
| 支柱一致性 | ×1.18 |
| 不计入评分 | |
| 价格波动 参考 | -0.9 |
| 最终评分 | 0.85 |
|
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 11.96% |
| 机构持股比例 | 90.75% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Montanova Capital, Llc | 30 Jun 2026 | 10,286,937 |
| Infinitum Asset Management, Llc | 30 Jun 2026 | 6,250,000 |
| Royalty Pharma Sub-Manager, Llc | 30 Jun 2026 | 2,936,507 |
| Cormorant Asset Management, Lp | 30 Jun 2026 | 2,610,000 |
该时间范围内无数据。
该时间范围内无数据。
投资组合